Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme, Targacept to Co-Develop Bioassays for CNS Disease

NEW YORK, May 22 - Tranzyme and Targacept said today they will team to develop a bioassay that might help discover drugs for central nervous system disorders.


The deal, which the firms say also includes a licensing component, calls for Tranzyme to use its TranzVector gene-transfer technology and TranzAssay assay-development tool to create a cell-based assay to express a CNS-based receptor provided by Targacept.


Targacept will enrich Tranzyme with developmental support and royalties on sales of any products screened by Targacept with the assay. Tranzyme also will retain the rights to develop the bioassay for its own neurosensory drug discovery.


Click here for more information.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.